Legend:
CC = Vancouver Convention Centre
F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
674 !
Thu, 8/2/2018,
10:30 AM -
12:20 PM
CC-West 119
Adaptive Design - 3 — Contributed Papers
Biopharmaceutical Section
Chair(s): Ying Grace Li, Eli Lilly and Company
10:35 AM
A Bayesian Adaptive Phase 1/2 Design of Cisplatin and Cabazitaxel in Prostate Cancer with Visceral Metastasis
Mourad Tighiouart, Cedars-Sinai Medical Center
10:50 AM
Adaptive Bayesian Interval-Based Oncology Dose Finding Design with Quasi-Continuous Toxicity Model
Ling Wang, Takeda
11:05 AM
Bias-Corrected Estimation of Treatment Effects in Biomarker-Based Adaptive Subgroup Analysis: New Approach Based on Randomized Tests with Smooth Rejection Function
Kiichiro Toyoizumi, Shionogi Inc. ; Shigeyuki Matsui, Nagoya University
11:20 AM
Practical Considerations of Subgroups Quantification, Selection and Adaptive Enrichment in Confirmatory Trials
Jianchang Lin, Takeda Pharmaceuticals ; Rachael Liu, Takeda Pharmaceuticals ; Veronica Bunn, Florida State University
11:35 AM
An Adaptive Dose Selection Case Study: Statistical Methods and Operational Considerations
Adam Hamm, Cytel, Inc.
11:50 AM
Statistical Monitoring of Semi-Competing Risk Outcomes in Clinical Trials
Toshi Hamasaki ; Scott Evans, Harvard University; Tomoyuki Sugimoto, Kagoshima University; Koko Asakura, National Cerebral and Cardiovascular Center; Susan Halabi, Duke University
12:05 PM
BOIN-ET: Bayesian Optimal Interval Design for Dose Finding Based on Both Efficacy and Toxicity Outcomes
Kentaro Takeda, Astellas Pharma Global Development, Inc. ; Masataka Taguri, Yokohama City University; Satoshi Morita, Kyoto University
